LBA45 Overall survival (OS) outcomes from NRG-GY004, a phase III study comparing single-agent olaparib or combination cediranib and olaparib to platinum (Plat) based chemotherapy in recurrent plat sensitive ovarian cancer (OvCa)
| Autor: | Liu, J.F., Brady, M., Matulonis, U.A., Miller, A., Kohn, E.C., Swisher, E., Tew, W., Cloven, N., Muller, C., Bender, D., Moore, R., Michelin, D., Waggoner, S., Geller, M., Fujiwara, K., D'Andre, S., Carney, M., Secord, A.A., Walker, J., Bookman, M.A. |
|---|---|
| Zdroj: | In Annals of Oncology October 2023 34 Supplement 2:S1285-S1285 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|